Literature DB >> 27755232

FIB-4 and imaging for measuring fibrosis in hepatitis C virus.

Barbara J Turner1, Yuanyuan Liang, Amit G Singal.   

Abstract

OBJECTIVES: Noninvasive measures are widely used to assess fibrosis and may be used to prioritize hepatitis C virus (HCV) treatment. We examined risks for likely fibrosis in patients with chronic HCV infection using fibrosis-4 (FIB-4) and imaging. PATIENTS AND METHODS: A HCV screening program diagnosed chronic HCV in patients born from 1945 to 1965 admitted in a safety net hospital. Likely fibrosis was based on FIB-4 (≥1.45) alone or combined with imaging interpreted as fibrosis or cirrhosis. Logistic regression was used to calculate adjusted odds ratios (AORs) for demographic, clinical, and insurance factors associated with each outcome. Using multiple linear regression among patients with likely fibrosis, we examined associations with higher Model for End-Stage Liver Disease (MELD) scores.
RESULTS: Using FIB-4 alone, 57% (83/146) of patients had likely fibrosis versus 43% (63/148) using FIB-4 plus imaging. Obesity/overweight and Hispanic ethnicity had over three-fold to four-fold higher AORs for fibrosis, respectively, based on FIB-4 plus imaging, but both AORs were only two-fold greater with FIB-4 alone. Being uninsured was significantly associated with fibrosis based on FIB-4 alone [AOR=2.40 (95% confidence interval 1.01-5.70)] but not with imaging. Heavy alcohol use and older age were associated with higher AORs of fibrosis with both measures (all P<0.004). MELD scores were ∼3 points higher for uninsured patients, regardless of measure (both P<0.05).
CONCLUSIONS: Using FIB-4 plus imaging to identify fibrosis in chronic HCV, higher risks are seen for Hispanics and overweight/obese individuals than using FIB-4 alone. Higher MELD scores at diagnosis for the uninsured indicate delayed access to care.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27755232     DOI: 10.1097/MEG.0000000000000766

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  3 in total

Review 1.  Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.

Authors:  Allison E Wang; Eric Hsieh; Barbara J Turner; Norah Terrault
Journal:  J Gen Intern Med       Date:  2022-04-28       Impact factor: 6.473

2.  The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.

Authors:  Yu-Chi Lee; Tsung-Hui Hu; Chao-Hung Hung; Sheng-Nan Lu; Chien-Hung Chen; Jing-Houng Wang
Journal:  PLoS One       Date:  2019-04-02       Impact factor: 3.240

3.  Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination?

Authors:  Rosa López-Martínez; Andrea Arias-García; Francisco Rodríguez-Algarra; Laura Castellote-Bellés; Ariadna Rando-Segura; Guillermo Tarraso; Elena Vargas-Accarino; Isabel Montserrat-Lloan; Albert Blanco-Grau; Andrea Caballero-Garralda; Roser Ferrer-Costa; Tomas Pumarola-Sunye; Maria Buti-Ferret; Rafael Esteban-Mur; Josep Quer; Ernesto Casis-Saez; Francisco Rodríguez-Frías
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.